Ascendis Pharma (NasdaqGS:ASND) is back in focus after new Week 104 radiographic data from its pivotal ApproaCH trial of once weekly TransCon CNP in children with achondroplasia highlighted continued improvements in lower limb alignment and growth.

The fresh Week 104 ApproaCH data and February FDA approval sit alongside steady price momentum, with Ascendis Pharma posting a 1-day share price return of 2.51% and a 30-day share price return of 26.62%. The year to date share price return of 11.87% signals building interest rather than a short term spike.

If this kind of rare disease progress has your attention, it could be a good moment to look at other healthcare stocks using our screener for 40 healthcare AI stocks

With Ascendis Pharma trading at $274.50, an intrinsic value estimate suggesting a 59% discount, and a modest 6.5% gap to the average analyst target, the key question is whether investors are still early or if the market is already pricing in future growth.

Most Popular Narrative: 6.6% Undervalued

On the most followed narrative, Ascendis Pharma screens slightly undervalued, with a fair value of $293.79 against the latest close at $274.50. That gap rests on some specific growth and margin assumptions.

Ascendis Pharma focuses on developing and commercializing long acting therapies for rare endocrine and growth disorders using its TransCon technology platform.

Regulatory and commercial rollout of TransCon CNP in achondroplasia, including potential U.S. approval and ex U.S. launches, targets an area of clear unmet need where once weekly dosing and benefits beyond linear growth are a focus. This can support incremental revenue growth and scale benefits on selling and marketing expenses.

Curious what sits behind that rare disease thesis and the current fair value gap for Ascendis Pharma? The core narrative links accelerating revenue, shifting margins and a future earnings multiple that assumes investors stay comfortable treating Ascendis more like a scaled cash generator than an early stage biotech. The tension is in how quickly those long acting therapies translate into the cash flows that model expects.

Result: Fair Value of $293.79 (UNDERVALUED)

However, Ascendis Pharma still faces execution risk if Yorvipath uptake slows, or if TransCon CNP approvals, labels, or real world use turn out weaker than current expectations.

Another View on Ascendis Pharma: P/E Signals a Richer Price

The first narrative frames Ascendis Pharma as modestly undervalued, yet the current P/E of 30.1x tells a different story when set against the US Biotechs industry at 16.8x and a peer average of 39.1x. That premium to the industry, but discount to peers, leaves a simple question: is this valuation cushion or valuation risk?

To see how this pricing gap fits into a fuller view of Ascendis Pharma, including earnings quality and future expectations, check out the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Mixed messages on Ascendis Pharma so far, with both risks and rewards in play. Move quickly, test the assumptions and see how they stack up against the 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Ascendis Pharma?

If Ascendis Pharma has sharpened your focus, do not stop here. Use the Simply Wall St Screener to spot more opportunities that match your style.

• Target potential mispricings by scanning for companies trading below their estimated worth using the 43 high quality undervalued stocks.
• Strengthen your income stream by filtering for stocks with higher yields and resilient payouts through the 7 dividend fortresses.
• Limit downside surprises by zeroing in on businesses with lower risk profiles via the 75 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.